Portrait of Jacques Corbeil

Jacques Corbeil

Affiliate Member
Full Professor, Université Laval
General Partner et CSO, Linearis Venture and Labs
Research Topics
AI and Healthcare
Applied Machine Learning
Computational Biology
Website
Google Scholar
LinkedIn

Biography

Dr. Jacques Corbeil focuses on using the latest techniques in bioinformatics and machine learning to assist diagnostic, prognostic and response to treatment. Modern genomics and metabolomics techniques generate a deluge of data that needs to be interpreted using novel informatics approaches. Dr. Corbeil uses state-of-the-art instrumentation and methodologies to facilitate the interpretation of complex data, including high throughput mass spectrometry, in particular, metabolomics and next-gen sequencing.

Dr. Corbeil’s research includes investigating how infectious microorganisms interact with their host, the effects of antibiotics on our microbial flora and the environment, and exploring how to design small molecules and drugs to interfere with specific microbial functions and cancer progression. Operating at the interface of machine learning and omics sciences, he specializes in big data analytics applied to infectious diseases and cancer and he has expertise in the integration of omics data. Dr. Corbeil collaborates with many industries to ameliorate their process and implement artificial intelligence strategies. Since 2004, Dr. Corbeil holds the Canada Research Chair in Medical Genomics (Tier 1).

Publications

QMAP: A Benchmark for Standardized Evaluation of Antimicrobial Peptide MIC and Hemolytic Activity Regression
Anthony Lavertu
Jacques Corbeil
Pascal Germain
Antimicrobial peptides (AMPs) are promising alternatives to conventional antibiotics, but progress in computational AMP discovery has been d… (see more)ifficult to quantify due to inconsistent datasets and evaluation protocols. We introduce QMAP, a domain-specific benchmark for predicting AMP antimicrobial potency (MIC) and hemolytic toxicity (HC50) with homology-aware, predefined test sets. QMAP enforces strict sequence homology constraints between training and test data, ensuring that model performance reflects true generalization rather than overfitting. Applying QMAP, we reassess existing MIC models and establish baselines for MIC and HC50 regression. Results show limited progress over six years, poor performance for high-potency MIC regression, and low predictability for hemolytic activity, emphasizing the need for standardized evaluation and improved modeling approaches for highly potent peptides. We release a Python package facilitating practical adoption, and with a Rust-accelerated engine enabling efficient data manipulation, installable with pip install qmap-benchmark.
2026-02-03
bioRxiv (preprint)
doi.org
Extracting a COVID-19 signature from a multi-omic dataset
Baptiste Bauvin
Thibaud Godon
Guillaume Bachelot
Claudia Carpentier
Riikka Huusaari
Maxime Déraspe
Juho Rousu
Caroline Quach
Jacques Corbeil
The complexity of COVID-19 requires approaches that extend beyond symptom-based descriptors. Multi-omic data, combining clinical, proteomic,… (see more) and metabolomic information, offer a more detailed view of disease mechanisms and biomarker discovery. As part of a large-scale Quebec initiative, we collected extensive datasets from COVID-19 positive and negative patient samples. Using a multi-view machine learning framework with ensemble methods, we integrated thousands of features across clinical, proteomic, and metabolomic domains to classify COVID-19 status. We further applied a novel feature relevance methodology to identify condensed signatures. Our models achieved a balanced accuracy of 89% ± 5% despite the high-dimensional nature of the data. Feature selection yielded 12- and 50-feature signatures that improved classification accuracy by at least 3% compared to the full feature set. These signatures were both accurate and interpretable. This work demonstrates that multi-omic integration, combined with advanced machine learning, enables the extraction of robust COVID-19 signatures from complex datasets. The condensed biomarker sets provide a practical path toward improved diagnosis and precision medicine, representing a significant advancement in COVID-19 biomarker discovery.
2025-09-21
Frontiers in Bioinformatics (published)
doi.org